G1 Therapeutics Inc
NASDAQ:GTHX

Watchlist Manager
G1 Therapeutics Inc Logo
G1 Therapeutics Inc
NASDAQ:GTHX
Watchlist
Price: 7.15 USD Market Closed
Market Cap: 377.2m USD

Intrinsic Value

The intrinsic value of one GTHX stock under the Base Case scenario is 5.49 USD. Compared to the current market price of 7.15 USD, G1 Therapeutics Inc is Overvalued by 23%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

GTHX Intrinsic Value
5.49 USD
Overvaluation 23%
Intrinsic Value
Price
Base Case Scenario

Valuation History
G1 Therapeutics Inc

Valuation History Unavailable

Historical valuation for GTHX cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%
Compare GTHX to

Fundamental Analysis

G1 Therapeutics Inc
NASDAQ:GTHX
US
Biotechnology
Market Cap
376.8m USD
IPO
May 17, 2017
US
Biotechnology
Market Cap
376.8m USD
IPO
May 17, 2017
Price
$false
EPS
$false
Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about GTHX?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about G1 Therapeutics Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
G1 Therapeutics Inc

Current Assets 92.9m
Cash & Short-Term Investments 60.7m
Receivables 13.3m
Other Current Assets 18.9m
Non-Current Assets 5.8m
PP&E 5.6m
Other Non-Current Assets 187k
Efficiency

Free Cash Flow Analysis
G1 Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
G1 Therapeutics Inc

Revenue
58.2m USD
Cost of Revenue
-6.1m USD
Gross Profit
52m USD
Operating Expenses
-89.9m USD
Operating Income
-37.9m USD
Other Expenses
-6.9m USD
Net Income
-44.8m USD
Fundamental Scores

GTHX Profitability Score
Profitability Due Diligence

G1 Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
ROIC is Increasing
Positive Revenue Growth Forecast
Negative 3-Years Revenue Growth
23/100
Profitability
Score

G1 Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

GTHX Solvency Score
Solvency Due Diligence

G1 Therapeutics Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
Average D/E
35/100
Solvency
Score

G1 Therapeutics Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GTHX Price Targets Summary
G1 Therapeutics Inc

There are no price targets for GTHX.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

G1 Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for GTHX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

GTHX Insider Trading
Buy and sell transactions by insiders

GTHX News

What is the Intrinsic Value of one GTHX stock?

The intrinsic value of one GTHX stock under the Base Case scenario is 5.49 USD.

Is GTHX stock undervalued or overvalued?

Compared to the current market price of 7.15 USD, G1 Therapeutics Inc is Overvalued by 23%.

Back to Top